134 results on '"Houghton M"'
Search Results
2. Slow recovery of stream invertebrates on subantarctic Macquarie Island after eradication of introduced rabbits and regrowth of vegetation
3. Anisotropic mechanical response of layered disordered fibrous materials
4. Strategies and Prospects for Vaccination Against the Hepatitis C Viruses
5. A196 IDENTIFICATION OF AN IMMUNOSUPPRESSIVE DOMAIN IN HUMAN BETARETROVIRUS
6. Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes
7. The Mars Atmosphere and Volatile Evolution (MAVEN) Mission
8. Effect of Immunosuppression on T-Helper 2 and B-Cell Responses to Influenza Vaccination
9. Induced Anisotropy in an Fe-27.5 Cr-17.5 Co-0.5 Al Alloy
10. Preliminary Assessment of the Geothermal Potential of the United Kingdom
11. Vaccine adjuvants – understanding molecular mechanisms to improve vaccines
12. HCV E1E 2‐ MF 59vaccine in chronic hepatitis C patients treated with PEG ‐ IFN α2a and R ibavirin: a randomized controlled trial
13. Changes in the innervation of the mouse internal anal sphincter during aging
14. Heat exchanger/catalytic system for reducing the exhaust emissions from diesel engines
15. Chimp Virus Makes a Savvy Vaccine Vector
16. Paul Winchester Houghton
17. ChemInform Abstract: Building BLOCKs in Synthesis. Part 5. Direct Formation of α-Dione BLOCKs from o-Benzoquinone Cycloadditions and Their Value in the Synthesis of Fused Quinoxalines, 1,10-Phenanthrolines and Pteridines.
18. A phase I study evaluating the relative bioavailability of S-1 capsules.
19. 602 THE CANDIDATE HCV E1E2MF59 VACCINE IS SAFE IN CHRONIC HEPATITIS C PATIENTS AND ACCELLERATES THE SECOND PHASE VIRAL DECLINE UPON PRIMARY RESPONSE TO PEG-INTERFERON-2A/RIBAVIRIN THERAPY
20. The candidate HCV E1E2MF59 vaccine enhances 2nd phase viral decline in responders to PEG-IFN/ribavirin
21. Delivering engineering safely at Sellafield
22. O.015 A phase 1 trial of a novel E1E2/MF59C.1 hepatitis C vaccine candidate in healthy HCV-negative adults (DMID 01-002)
23. Phase I study of S-1 administrated for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer (AUGIC)
24. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma (AGC)
25. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma (AGC)
26. Binding of HCV E2 to CD81 enhances surface expression of HLA-E
27. Down-regulation of CCR5 expression by hepatitis C virus
28. Disturbance reduction system: testing technology for precision formation control
29. Hepatitis C virus (HCV)-specific CD8+ T cells in patients with recurrent HCV-infection after liver transplantation (OLTx)
30. Only a strong, multispecific, and longlasting CD4+ T cell response is associated with viral elimination in patients with recurrent HCV-infection after OLTx
31. Intrahepatic HCV-Specific CD4+ T cells in chronic HCV-infection are multispecific and produce γ-IFN
32. A COMPARISON OF ATHLETIC ACHIEVEMENT AND EATING DISORDER BEHAVIORS AMONG FEMALE CROSS COUNTRY RUNNERS
33. Association of multispecific CD4+ response to hepatitis C and severity of recurrence after liver transplantation
34. Recurrence of hepatitis C virus after loss of virus specific CD4+ T cell response in acute hepatitis C
35. Response of T cells from HCV reinfected grafts after LTX resembles that of T cells from peripheral blood in acute hepatitis C
36. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients
37. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection
38. Hepatitis C virus core and E2 protein expression in transgenic mice
39. Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles
40. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C.
41. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients
42. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.
43. Human Specific CD4+ T Cell Response to Hepatitis Delta Virus
44. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
45. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.
46. ChemInform Abstract: Attachment of Chelating Capacity to (60)Fullerene via Short Rigid Rods.
47. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release.
48. Immune responses to plasmid DNA encoding the hepatitis C virus core protein
49. Cross-genotype hepatitis C virus (HCV)-specific cytotoxic T lymphocyte (CTL) activity in the liver in chronic hepatitis C
50. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.